These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: MAOA gene polymorphisms and response to mirtazapine in major depression.
    Author: Tzeng DS, Chien CC, Lung FW, Yang CY.
    Journal: Hum Psychopharmacol; 2009 Jun; 24(4):293-300. PubMed ID: 19382113.
    Abstract:
    BACKGROUND: Polymorphisms in the monoamine oxidase A (MAOA) gene may influence treatment outcomes in major depression disorder (MDD). OBJECTIVE: To investigate the association of MAOA genetic polymorphisms and response to mirtazapine in patients with MDD. METHOD: Fifty-eight adult patients in Taiwan who met the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) diagnostic criteria for MDD were given mirtazapine for 7 weeks and evaluated on days 0, 7, 14, 21, 49 using the 24-item Hamilton Rating Scale for Depression (HRSD). Remission was defined as a final HRSD <or= 10 and a 50% reduction in baseline HRSD score. Patients provided venous blood for DNA testing. The patients' response to mirtazapine treatment was compared between those who had the long-form polymorphism in the MAOA gene promoter and the short-form polymorphism. RESULT: The total HRSD scores after mirtazapine treatment were significantly lower than baseline (p < 0.001). There were 10 cases (38.5%) in short from and 6 (18.8%) in long from group touched the remission stage. Patients with the short-form group had a greater response to mirtazapine (p < 0.001) than those with the long-form polymorphism after controlling for age, sex, and apolipoprotein E genetic (APOE) polymorphism. CONCLUSION: The genetic polymorphisms in the MAOA promoter region may be associated with treatment response to mirtazapine.
    [Abstract] [Full Text] [Related] [New Search]